These findings led them to propose that the neutralization of endogenous INF during anti-TNF therapy might further switch the TNF/INF-α balance to a sustained IFN-α secretion by pDCs with a well-known pathogenic effect, and therefore a possible explanation to the lupus-like symptoms develop during TNF blockade. This evidence concerns the gene IFNA17 and systemic lupus erythematosus.